Value pool trajectory
Vietnam pharma sat at USD 7.6-8.0 bn in 2024-25 across reconciled estimators [Fortune BI 2025; Stellapharm 2025]. The headline trajectory points to USD 12.0-16.0 bn by 2030-32, with the spread driven by API and biologics inclusion. Our base case targets USD 12.0 bn by 2030 [Kira estimates] — conservatively below Fortune's 9.33% CAGR (USD 16.0 bn by 2032) but ahead of Statista's narrower 5.14% prescription-only path.
H1 2025 acceleration
H1 2025 spend reached VND 231 trillion (~USD 9 bn annualised), +9% YoY [VnEconomy 2025]. The pharmacy channel led with 11% growth while hospital channel grew 6% [VIRAC 2025]. The channel-split divergence is the central structural signal — chain pharmacies are absorbing share from both loose-counter retail and from hospital outpatient dispensing.
Per-capita context
Pharma spend per capita rises from ~USD 80 in 2025 toward USD 110 by 2030 [Kira estimates] — still ~half Thailand's level and ~one-third Malaysia's [Kira estimates]. The convergence math underwrites a structural growth premium versus mature peers; volume — not price — is the dominant lever through 2030.
Methodology note: Market sizing triangulates Fortune Business Insights' USD 16 bn 2032 forecast [Fortune BI 2025], Stellapharm's channel-split briefing [Stellapharm 2025], and VnEconomy's H1 2025 spending data [VnEconomy 2025]. Statista's narrower USD 2.4 bn 2025 figure tracks prescription-only drugs; KIRA's base case uses the broader definition (finished-dose generics + OTC + functional-food-adjacent). ~28% of quantitative claims in this article carry [Kira estimates] tags indicating KIRA in-house analyst triangulation. Forecasts reflect KIRA's analyst view as of May 2026. No part of this article constitutes investment advice.